Aurion Biotech Pitch Deck Breakdown (2022 Deck, 25 Slides)

Introduction and Vision

The Aurion Biotech pitch deck, dated Q1 2022, opens with a clear and focused value proposition: curing blindness through cell therapy. The cover slide (Slide 1) introduces CEO Greg Kunst and CFO David Rostov, setting a professional tone with high-quality medical imagery. The company positions itself not just as a biotech startup, but as a clinical-stage entity with a transformational platform.

The Core Innovation

Slide 3 provides a high-level overview of the solution. It identifies that corneal endothelial disease affects 16 million people in the US, EU, and Japan. The technical breakthrough is twofold: first, the ability to manufacture corneal endothelial cells in vitro, and second, the efficiency of the process. The deck states that cells from one donor can produce 100+ cell therapy treatments. This is a critical point for investors, as it addresses the primary bottleneck in corneal health: the scarcity of donor tissue. The slide also notes that vision is restored within days of the injection.

Historical Context and Traction

Slide 5 presents a comprehensive timeline titled 'Aurion Biotech At a Glance.' It traces the company's roots back to a research collaboration between KPUM and Professor Kinoshita starting in 2005. Key milestones include a $37M Series B in 2018-19 and the acquisition of cell therapy IP in 2020. The timeline highlights the company's evolution from a research project to a CorneaGen spin-out in 2021, culminating in the 2022 goal of Japan NDA and US IND submissions. This timeline demonstrates nearly two decades of foundational work, which is essential for establishing credibility in the biotech sector.

The Market Opportunity

Patient Impact and Need

Slide 7 uses visual aids to communicate the patient perspective of corneal blindness. It shows the progression from a cloudy cornea to glare, halos, and eventually blurred vision. By visualizing the problem, the deck moves beyond abstract statistics to the reality of the patient experience. This emotional hook is immediately followed by the hard data of the market opportunity.

Quantifying the TAM

On Slide 9, Aurion quantifies the market. They note that 4% of the population age 40+ have corneal endothelial disease. The total prevalence is 16 million people, with an annual incidence of 500,000. The company calculates a $4.75 Billion Total Addressable Market (TAM) based on 475,000 eyes multiplied by a $10,000 per procedure price point. Crucially, they point out that fewer than 70,000 patients are currently treated annually, highlighting a massive underserved market due to current surgical and supply limitations.

The Solution: Key Success Factors

Competitive Advantages

Slide 11 outlines why Aurion's therapy is positioned to win. It lists four key success factors: solving the unmet need for donor tissue (1 donor to 100+ treatments), a simple 10-minute injection, broad accessibility for ophthalmologists to learn, and favorable economics. The mention of 'Medicare Part-B injectable' is a strategic inclusion, signaling to investors that the company has already considered the reimbursement landscape in the US, which is often a major hurdle for new therapies.

The Procedure

Slide 13 details the 'How it Works' of the procedure. It involves removing the diseased endothelium, injecting the cells in suspension into the patient's anterior chamber, and a recovery period where the patient remains in a prone position. The simplicity of an injection versus a full transplant is a recurring theme, emphasizing the potential for rapid clinical adoption.

Clinical Validation

Long-Term Safety and Efficacy

Slide 15 is perhaps the most important slide in the deck for a clinical-stage company. it presents data from the first 11 patients in Japan, with follow-up stretching to five years. The results are significant: mean corneal thickness dropped from 743μm to 555μm (within the healthy range), and mean visual acuity improved from 20/220 to 20/30. The slide proudly displays logos from the New England Journal of Medicine and Ophthalmology, citing peer-reviewed validation. The fact that there were 'No serious adverse events' over five years provides the long-term safety profile that regulatory bodies and investors demand.

Strategic Roadmap and Team

Regulatory and Manufacturing Focus

Slides 17 and 19 serve as section dividers for the 'US Clinical Development Plan' and 'Manufacturing / IP.' While the specific details of these plans are not fully expanded in the provided slides, their inclusion in the table of contents indicates a structured approach to the two biggest risks in biotech: regulatory approval and scalable production.

Management Pedigree

Slide 21 introduces the management team. The roster is impressive, featuring executives with backgrounds at Alcon, Novartis, Biogen, and Bausch & Lomb. For example, CEO Greg Kunst comes from Glaukos and Alcon, while CSO Arnaud Lacoste led cell and gene therapy at Novartis. This 'who's who' of ophthalmology and biotech leadership is designed to convince investors that the company has the operational expertise to navigate the complex path to commercialization.

Investment Highlights Summary

Slide 23 summarizes the investment case. It reiterates the $4.75B market, the clinical validation of 100+ patients treated, and the well-defined regulatory pathway for 2H 2022. It also introduces the idea of a 'leverageable platform,' suggesting that the technology could eventually be applied to glaucoma and AMD (Age-related Macular Degeneration). Finally, it lists high-profile investors like KKR's Falcon Vision and Petrichor, signaling that the company already has the backing of sophisticated institutional capital.

What Works and What is Missing

Strengths of the Deck

The Aurion Biotech deck excels at de-risking a high-stakes investment. By leading with 5-year clinical data and peer-reviewed citations, they move the conversation from 'if it works' to 'how fast can we scale.' The manufacturing slide (Slide 3) is a standout because it addresses the economic viability of the product—turning one donor into 100 doses is a 100x improvement in supply chain efficiency. The team slide is also exceptionally strong, showing a deep bench of industry veterans rather than first-time founders.

Omissions and Weaknesses

Despite its strengths, the deck has notable omissions. There is no detailed financial slide showing the use of proceeds for the $120M raise, nor are there specific projections for revenue or burn rate. While the 'Favorable Economics' are mentioned, a more detailed breakdown of the cost of goods sold (COGS) versus the $10k price point would have strengthened the business case. Additionally, the competitive landscape is largely ignored; while they mention the 'current standard of care,' they do not name other biotech firms working on similar cell therapies or gene therapies for the cornea.

Founder's Guide: What to Copy

Founders in the deep tech or biotech space should emulate Aurion's use of 'Social Proof' through clinical journals. Citing the New England Journal of Medicine is more powerful than any internal metric. Furthermore, the way Aurion framed their 'Manufacturing' breakthrough as a solution to a 'Supply' problem is a brilliant way to explain technical innovation in business terms. Finally, the 'Investment Highlights' slide (Slide 23) is a perfect example of a closing slide—it synthesizes the entire pitch into five digestible bullet points that an investor can easily relay to their partners.